Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy

G. Querques, L. Querques, N. Leveziel, F. Bandello, E. H. Souied

Research output: Contribution to journalArticle

Abstract

Purpose: To describe the results obtained with intravitreal ranibizumab injections in a patient with adult onset foveomacular vitelliform dystrophy (AOFVD) complicated by Type 3 choroidal neovascularization (CNV). Methods: A 78-year old man diagnosed with AOFVD presented at our department for decreased vision in his left eye (LE) (20/80). Upon a complete ophthalmologic examination, including fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography, the patient was diagnosed with Type 3 CNV. Three monthly injections of ranibizumab 0.05 ml/0.5 mg were administered intravitreally without complications. Results: After the first injection, visual acuity of the LE improved (20/64) and regression of the Type 3 CNV was observed by fluorescein angiography, indocyanine green angiography and OCT. Six months after the final ranibizumab injection, a more-or-less complete resolution of the exudative retinal changes was observed. Conclusions: Type 3 CNV may be associated with AOFVD. Intravitreal ranibizumab may represent a possible therapeutic option in this unusual context.

Original languageEnglish
JournalJournal Francais d'Ophtalmologie
Volume36
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Vitelliform Macular Dystrophy
Choroidal Neovascularization
Indocyanine Green
Fluorescein Angiography
Injections
Angiography
Intravitreal Injections
Optical Coherence Tomography
Visual Acuity
Ranibizumab

Keywords

  • Adult onset foveomacular vitelliform dystrophy
  • Age-related macular degeneration
  • Fluorescein angiography
  • Indocyanine green angiography
  • Lucentis
  • Ranibizumab
  • Retinal angiomatous proliferation
  • Retinal-choroidal anastomosis
  • Spectral-domain optical coherence tomography
  • Type 3 choroidal neovascularization
  • Vitelliform macular dystrophy

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy. / Querques, G.; Querques, L.; Leveziel, N.; Bandello, F.; Souied, E. H.

In: Journal Francais d'Ophtalmologie, Vol. 36, No. 1, 01.2013.

Research output: Contribution to journalArticle

@article{581f91ace3684a388f44d0152af483fd,
title = "Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy",
abstract = "Purpose: To describe the results obtained with intravitreal ranibizumab injections in a patient with adult onset foveomacular vitelliform dystrophy (AOFVD) complicated by Type 3 choroidal neovascularization (CNV). Methods: A 78-year old man diagnosed with AOFVD presented at our department for decreased vision in his left eye (LE) (20/80). Upon a complete ophthalmologic examination, including fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography, the patient was diagnosed with Type 3 CNV. Three monthly injections of ranibizumab 0.05 ml/0.5 mg were administered intravitreally without complications. Results: After the first injection, visual acuity of the LE improved (20/64) and regression of the Type 3 CNV was observed by fluorescein angiography, indocyanine green angiography and OCT. Six months after the final ranibizumab injection, a more-or-less complete resolution of the exudative retinal changes was observed. Conclusions: Type 3 CNV may be associated with AOFVD. Intravitreal ranibizumab may represent a possible therapeutic option in this unusual context.",
keywords = "Adult onset foveomacular vitelliform dystrophy, Age-related macular degeneration, Fluorescein angiography, Indocyanine green angiography, Lucentis, Ranibizumab, Retinal angiomatous proliferation, Retinal-choroidal anastomosis, Spectral-domain optical coherence tomography, Type 3 choroidal neovascularization, Vitelliform macular dystrophy",
author = "G. Querques and L. Querques and N. Leveziel and F. Bandello and Souied, {E. H.}",
year = "2013",
month = "1",
doi = "10.1016/j.jfo.2012.04.013",
language = "English",
volume = "36",
journal = "Journal Francais d'Ophtalmologie",
issn = "0181-5512",
publisher = "Elsevier Masson",
number = "1",

}

TY - JOUR

T1 - Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy

AU - Querques, G.

AU - Querques, L.

AU - Leveziel, N.

AU - Bandello, F.

AU - Souied, E. H.

PY - 2013/1

Y1 - 2013/1

N2 - Purpose: To describe the results obtained with intravitreal ranibizumab injections in a patient with adult onset foveomacular vitelliform dystrophy (AOFVD) complicated by Type 3 choroidal neovascularization (CNV). Methods: A 78-year old man diagnosed with AOFVD presented at our department for decreased vision in his left eye (LE) (20/80). Upon a complete ophthalmologic examination, including fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography, the patient was diagnosed with Type 3 CNV. Three monthly injections of ranibizumab 0.05 ml/0.5 mg were administered intravitreally without complications. Results: After the first injection, visual acuity of the LE improved (20/64) and regression of the Type 3 CNV was observed by fluorescein angiography, indocyanine green angiography and OCT. Six months after the final ranibizumab injection, a more-or-less complete resolution of the exudative retinal changes was observed. Conclusions: Type 3 CNV may be associated with AOFVD. Intravitreal ranibizumab may represent a possible therapeutic option in this unusual context.

AB - Purpose: To describe the results obtained with intravitreal ranibizumab injections in a patient with adult onset foveomacular vitelliform dystrophy (AOFVD) complicated by Type 3 choroidal neovascularization (CNV). Methods: A 78-year old man diagnosed with AOFVD presented at our department for decreased vision in his left eye (LE) (20/80). Upon a complete ophthalmologic examination, including fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography, the patient was diagnosed with Type 3 CNV. Three monthly injections of ranibizumab 0.05 ml/0.5 mg were administered intravitreally without complications. Results: After the first injection, visual acuity of the LE improved (20/64) and regression of the Type 3 CNV was observed by fluorescein angiography, indocyanine green angiography and OCT. Six months after the final ranibizumab injection, a more-or-less complete resolution of the exudative retinal changes was observed. Conclusions: Type 3 CNV may be associated with AOFVD. Intravitreal ranibizumab may represent a possible therapeutic option in this unusual context.

KW - Adult onset foveomacular vitelliform dystrophy

KW - Age-related macular degeneration

KW - Fluorescein angiography

KW - Indocyanine green angiography

KW - Lucentis

KW - Ranibizumab

KW - Retinal angiomatous proliferation

KW - Retinal-choroidal anastomosis

KW - Spectral-domain optical coherence tomography

KW - Type 3 choroidal neovascularization

KW - Vitelliform macular dystrophy

UR - http://www.scopus.com/inward/record.url?scp=84873709484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873709484&partnerID=8YFLogxK

U2 - 10.1016/j.jfo.2012.04.013

DO - 10.1016/j.jfo.2012.04.013

M3 - Article

C2 - 23218864

AN - SCOPUS:84873709484

VL - 36

JO - Journal Francais d'Ophtalmologie

JF - Journal Francais d'Ophtalmologie

SN - 0181-5512

IS - 1

ER -